Supernus Pharmaceuticals Inc (SUPN) — Cash Flow Quality Index
Supernus Pharmaceuticals Inc (SUPN) has a Cash Flow Quality Index of 2.60x as of June 2025. Operating cash flow of $58.53 Million exceeds net income of $22.50 Million, indicating high earnings quality where cash backs reported profits. Explore Supernus Pharmaceuticals Inc (SUPN) cash conversion ratio to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Supernus Pharmaceuticals Inc Cash Flow Quality Index (2009–2024)
Historical Cash Flow Quality Index for Supernus Pharmaceuticals Inc across 12 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Supernus Pharmaceuticals Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Supernus Pharmaceuticals Inc (2009–2024)
Year-by-year earnings quality comparison for Supernus Pharmaceuticals Inc. For live market cap and the full company financial profile, see market cap of Supernus Pharmaceuticals Inc.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 2.33x | $171.95 Million | $73.86 Million | ▼ -97.2% |
| 2023 | 84.41x | $111.08 Million | $1.32 Million | ▲ +4286.6% |
| 2022 | 1.92x | $116.83 Million | $60.71 Million | ▼ -19.1% |
| 2021 | 2.38x | $127.13 Million | $53.42 Million | ▲ +118.3% |
| 2020 | 1.09x | $138.40 Million | $126.95 Million | ▼ -13.9% |
| 2019 | 1.27x | $143.13 Million | $113.06 Million | ▲ +8.9% |
| 2018 | 1.16x | $128.99 Million | $110.99 Million | ▼ -41.9% |
| 2017 | 2.00x | $114.64 Million | $57.28 Million | ▲ +173.2% |
| 2016 | 0.73x | $66.81 Million | $91.22 Million | ▼ -68.0% |
| 2015 | 2.29x | $32.12 Million | $14.02 Million | ▲ +488.9% |
| 2014 | 0.39x | $7.73 Million | $19.87 Million | ▼ -38.9% |
| 2009 | 0.64x | $2.63 Million | $4.14 Million | — |